Penn Pharma Celebrates 4 Years Accident Free
Pharmaceutical manufacturer Penn Pharma, a PCI company, has reached another significant safety milestone this month having operated for four years without a single accident at its facility in Tredegar, South Wales.
This landmark equates to 2.4 million working hours worked by approximately 300 staff and is a record that Penn, now a PCI company, is extremely proud of. Backed by a recent ISO14001 re-certification, the company places equal emphasis on its environmental management system and compliance.
To achieve this record in a standard day-to-day operational environment would be remarkable; however it is even more significant given the substantial expansion programmes undertaken at the site in the last 4 years. First, there was the design and build of the new contained manufacturing facility for the development and manufacturing of highly potent compounds which completed in September 2013, followed by a further capacity expansion resulting in a new large-scale commercial manufacturing suite which became operational in June 2014. Both expansion programmes were completed in less than 12 months, but not at the expense of safety.
To undertake such significant construction programmes while maintaining operational functionality elsewhere in the site and still remain accident free is a truly remarkable achievement and one of which the company and its employees are extremely proud.
Commenting on this latest milestone, Mark Dean-Netscher Vice President, International Operations said: “This type of achievement in safety does not just happen; we have created a safety focused culture by developing robust processes including a very effective ’near miss’ system. When we talk about safety within the business, there is a real sense of pride evident and it is the commitment of our staff which has led to this incredible achievement.”
Mark continued: “Customers can be confident that with this industry benchmark, Penn is uniquely placed as an outsourcing partner. We offer a guaranteed ‘safe pair of hands’ in the extended supply chain.”
This latest announcement is just one of a long list of achievements enjoyed by Penn in recent months; in 2014 Penn won the Facility Integration category at the ISPE Facility of the Year for its new contained manufacturing facility, as well as being awarded three CMO Leadership Awards.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.